PPARGC1A and metabolic dysfunction-associated steatotic liver disease: We recently reported the recruitment of both PGC1α and SRC1 peptides to PPARα/δ/γ-LBDs by fibrates (bezafibrate, fenofibric acid, and pemafibrate) and candidate anti-NAFLD PPAR agonists (pioglitazone, elafibranor, lanifibranor, saroglitazar, and seladelpar) using a TR-FRET assay [19,20].